Saltar al contenido
Merck

Arginine vasopressin receptor 2 activation promotes microvascular permeability in sepsis.

Pharmacological research (2020-11-08)
Ernesto Lopez, Satoshi Fukuda, Katalin Modis, Osamu Fujiwara, Baigal Enkhtaivan, Raul Trujillo-Abarca, Koji Ihara, Francisco Lima-Lopez, Dannelys Perez-Bello, Csaba Szabo, Donald S Prough, Perenlei Enkhbaatar
RESUMEN

Methicillin-resistant Staphylococcus aureus (MRSA) sepsis is a severe condition associated with vascular leakage and poor prognosis. The hemodynamic management of sepsis targets hypotension, but there is no specific treatment available for vascular leakage. Arginine vasopressin (AVP) has been used in sepsis to promote vasoconstriction by activating AVP receptor 1 (V1R). However, recent evidence suggests that increased fluid retention may be associated with the AVP receptor 2 (V2R) activation worsening the outcome of sepsis. Hence, we hypothesized that the inhibition of V2R activation ameliorates the severity of microvascular hyperpermeability during sepsis. The hypothesis was tested using a well-characterized and clinically relevant ovine model of MRSA pneumonia/sepsis and in vitro assays of human lung microvascular endothelial cells (HMVECs). in vivo experiments demonstrated that the treatment of septic sheep with tolvaptan (TLVP), an FDA-approved V2R antagonist, significantly attenuated the sepsis-induced fluid retention and markedly reduced the lung water content. These pathological changes were not affected by the treatment with V2R agonist, desmopressin (DDAVP). Additionally, the incubation of cultured HMVECs with DDAVP, and DDAVP along with MRSA significantly increased the paracellular permeability. Finally, both the DDAVP and MRSA-induced hyperpermeability was significantly attenuated by TLVP. Subsequent protein and gene expression assays determined that the V2R-induced increase in permeability is mediated by phospholipase C beta (PLCβ) and the potent permeability factor angiopoietin-2. In conclusion, our results indicate that the activation of the AVP-V2R axis is critical in the pathophysiology of severe microvascular hyperpermeability during Gram-positive sepsis. The use of the antagonist TLVP should be considered as adjuvant treatment for septic patients. The results from this clinically relevant animal study are highly translational to clinical practice.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Cóctel de inhibidores de proteasas, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
Suero fetal bovino, USA origin, sterile-filtered, suitable for cell culture, suitable for hybridoma
Sigma-Aldrich
Anti--actina antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Microvascular Endothelial Cell Growth Medium (500ml)